Kevin J. Freise, Ph.D.
Affiliations: | 2009 | Pharmacy | University of Iowa, Iowa City, IA |
Area:
PharmacologyGoogle:
"Kevin Freise"Parents
Sign in to add mentor| Peter Veng-Pedersen | grad student | 2009 | University of Iowa | |
| (Cellular lifespan based pharmacodynamic analysis of erythropoiesis.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Gopalakrishnan S, Wierda W, Chyla B, et al. (2020) Integrated mechanistic model of minimal residual disease kinetics with venetoclax therapy in chronic lymphocytic leukemia. Clinical Pharmacology and Therapeutics |
| Alhadab AA, Salem AH, Freise KJ. (2020) Semi-Mechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin. Clinical and Translational Science |
| Deng R, Gibiansky L, Lu T, et al. (2019) Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study. Leukemia & Lymphoma. 1-10 |
| Deng R, Gibiansky L, Lu T, et al. (2019) Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. Clinical Pharmacokinetics |
| Wang M, Ramchandren R, Chen R, et al. (2019) RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE SYMPATICO STUDY EVALUATING IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA Hematological Oncology. 37: 333-335 |
| Pang Y, Rosebraugh MR, Freise KJ, et al. (2018) Are Clinical Therapeutic Protein-Drug Interaction Studies Needed When Disease Modification Is Driving the Potential Interaction? Journal of Clinical Pharmacology |
| Mangal N, Salem AH, Menon RM, et al. (2018) Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials. Hematological Oncology |
| Freise KJ, Hu B, Salem AH. (2018) Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. European Journal of Clinical Pharmacology |
| Bueno O, Slimp R, Jacobson M, et al. (2018) A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma. Journal of Clinical Oncology. 36: TPS8061-TPS8061 |
| Costa LJ, Stadtmauer EA, Morgan GJ, et al. (2018) Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 36: 8004-8004 |